FTC Staff Issues FY 2017 Report on Branded Drug Firms' Patent Settlements with Generic Competitors* The number of reverse-payment agreements remains low; for the first time since FY 2004, no agreement contains a no-AG commitment. According to a new FTC staff report, the total number of final Hatch-Waxman patent settlements entered by pharmaceutical companies in FY 2017 was close to the record high in FY 2016. Despite the high number of
The US FTC issues a FY 2017 report on branded drug firms’ patent settlements with generic competitors
L'accès à cet article est réservé aux abonnés
Déjà abonné ? Identifiez-vous
L’accès à cet article est réservé aux abonnés.
Lire gratuitement un article
Vous pouvez lire cet article gratuitement en vous inscrivant.